Myostin Therapeutics Pty Ltd is a biotechnology company developing novel therapeutic interventions for the treatment of muscular diseases. Myostin’s commercial strategy is based on its unique proprietary myostatin inhibitors’ technologies.
The company’s initial indication will target the musculature of Duchenne Muscular Dystrophy (DMD) patients. In parallel, the company seeks to develop its interest in many other muscle wasting debilitating conditions such as Fascioscapular Humeral Dystrophy (FSHD), Amyotrophic Lateral Sclerosis (ALS) and cancer cachexia as well as age-related loss of muscle mass (sarcopenia).
Myostin is also open to engage with industry and academia to established strategic alliances to extend the applications of its propietary technology.
For more information please Contact Us